Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
You may also be interested in...
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.